Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Scilex Holding Yönetim

Yönetim kriter kontrolleri 0/4

Scilex Holding's CEO is Jaisim Shah, appointed in Nov 2022, has a tenure of 1.92 years. total yearly compensation is $7.37M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $187.90K. The average tenure of the management team and the board of directors is 1.9 years and 1.1 years respectively.

Anahtar bilgiler

Jaisim Shah

İcra Kurulu Başkanı

US$7.4m

Toplam tazminat

CEO maaş yüzdesi	12.4%
CEO görev süresi	1.9yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.9yrs
Yönetim Kurulu ortalama görev süresi	1.1yrs

Son yönetim güncellemeleri

Recent updates

Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically

Jun 14

It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks

Apr 24

Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues

Feb 28

Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)

Dec 21

Scilex Holding Company's (NASDAQ:SCLX) 56% Dip In Price Shows Sentiment Is Matching Earnings

May 06

CEO Tazminat Analizi

Jaisim Shah'un ücretlendirmesi Scilex Holding'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$172m
Mar 31 2024	n/a	n/a	-US$161m
Dec 31 2023	US$7m	US$917k	-US$167m
Sep 30 2023	n/a	n/a	-US$163m
Jun 30 2023	n/a	n/a	-US$54m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$786k	US$773k	-US$23m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	n/a	n/a	-US$81m
Mar 31 2022	n/a	n/a	-US$78m
Dec 31 2021	US$881k	US$579k	-US$88m

Tazminat ve Piyasa: Jaisim's total compensation ($USD7.37M) is above average for companies of similar size in the US market ($USD667.78K).

Tazminat ve Kazançlar: Jaisim's compensation has increased whilst the company is unprofitable.

CEO

Jaisim Shah (64 yo)

1.9yrs

Görev süresi

US$7,373,977

Tazminat

Mr. Jaisim Shah serves as Chief Executive Officer and President of SCILEX Pharmaceuticals, Inc. since March 2019. He serves as Chief Executive Officer, President and Director of Scilex Holding Company sinc...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Henry Ji	Executive Chairman	1.1yrs	US$33.92m	0.46% $ 563.2k
Jaisim Shah	President	1.9yrs	US$7.37m	0.15% $ 187.9k
Stephen Ma	Senior VP	1.1yrs	US$2.14m	0.012% $ 14.9k
Suketu Desai	CTO & Senior VP	1.9yrs	Veri yok	Veri yok
Gigi DeGuzman	Executive Director of Administrative Operations & Head of Human Resources	no data	Veri yok	Veri yok
Steven Lincoln	General Counsel & Chief Compliance Officer	no data	Veri yok	Veri yok
Sumant Rajendran	Executive Director of Marketing	no data	Veri yok	Veri yok
Mike Ciaffi	National Sales Director	no data	Veri yok	Veri yok
Suresh Khemani	Senior VP & Chief Commercial Officer	1.9yrs	US$456.82k	Veri yok
Dmitri Lissin	Senior VP & Chief Medical Officer	1.9yrs	US$528.83k	Veri yok
Elaine Chan	Executive Director & Head of Medical Affairs	2.8yrs	Veri yok	Veri yok

1.9yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: SCLX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Henry Ji	Executive Chairman	1.1yrs	US$33.92m	0.46% $ 563.2k
Jaisim Shah	President	1.9yrs	US$7.37m	0.15% $ 187.9k
David Lemus	Independent Director	1.9yrs	US$750.00k	0% $ 0
Yue Wu	Independent Director	1.1yrs	US$285.67k	0.0038% $ 4.6k
Dorman Followwill	Independent Director	1.9yrs	US$750.00k	0.00099% $ 1.2k
Jay Chun	Independent Director	1.1yrs	US$277.43k	0.082% $ 99.4k
Annu Navani	Director	less than a year	Veri yok	Veri yok

1.1yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SCLX's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Scilex Holding Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Scilex Holding Company Appoints Annu Navani as Board of Directors

President recently bought US$122k worth of stock

Scilex Holding Company, Annual General Meeting, Apr 05, 2024

High number of new and inexperienced directors

Scilex Holding Company Announces Management Changes

Scilex Holding Company Announces Management Changes

Recent updates

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA Label

Consensus EPS estimates fall by 62%, revenue upgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Scilex Holding Company Provides Preliminary Unaudited Sales Guidance for the Month Ended July 31, 2024

Scilex Holding Company Appoints Annu Navani as Board of Directors

Scilex Holding Company Announces Publication in Pain Journal Regarding Phase 3 Results of the Pivotal Registration Trial of Sp-102 (Semdexa™) in Lumbosacral Radicular Pain (Sciatica)

Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically

Consensus revenue estimates fall by 19%

Scilex Holding Company Announces FDA Approval of Commercial Manufacturing of Gloperba

President recently bought US$122k worth of stock

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Scilex Holding Company has completed a Follow-on Equity Offering in the amount of $15 million.

It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks

Scilex Holding Company has filed a Follow-on Equity Offering.

New minor risk - Market cap size

Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed

Scilex Holding Company and Scilex Pharmaceuticals, Inc. Announces Settlement Agreement with Takeda Pharmaceuticals Company Ltd and Takeda Pharmaceuticals U.S.A., Inc

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Scilex Holding Company, Annual General Meeting, Apr 05, 2024

Scilex Holding Company has filed a Follow-on Equity Offering.

Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues

Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023

Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

Scilex Holding Company has filed a Follow-on Equity Offering in the amount of $170 million.

Scilex Holding Company has filed a Follow-on Equity Offering in the amount of $170 million.

Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)

High number of new and inexperienced directors

Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal A High Degree of Interest in Gloperba as Liquid Colchicine Formulation Designed for Precision Dosing

Scilex Holding Company Announces ZTlido Will Be Added as a Preferred Agent to the Medicaid Preferred Drug List (PDL) in Two New States: One Midwestern and One Southern State

Scilex Holding Company Announces the Addition of Ztlido (Lidocaine Topical System) as A Preferred Agent to the Medicaid Preferred Drug List (Pdl) of the State of the State of Tennessee

Scilex Holding Company Announces Successful Fda Audit of Enhanced Ztlido®? Manufacturing Facility in Japan

Scilex Holding Company Announces Completion of Commercial Manufacturing of Gloperba

Scilex Holding Company Announces Completion of Commercial Manufacturing of Gloperba

Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs in Treating Acute Migraine Targeted by ELYXYB

Scilex Holding Company Announces Production Increase, Product Availability

Scilex Holding Company Announces Positive Type C Meeting with the Fda and Reaches Agreement on Path Forward to File an Nda for Sp-102 in Lumbosacral Radicular Pain (Sciatica)

Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders

Scilex Holding Company Announces Management Changes

Scilex Holding Company Announces Management Changes

Scilex Holding Company Announces the Completion of its SP-103 Phase 2

Scilex Holding Company Presents Oral and Poster Presentations on ZTlido (lidocaine Topical System) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV

Scilex Holding Company Provides Sales Guidance for the Month and Year to Date Ended August 31, 2023

Scilex Holding Company Announces Retirement of Jaisim Shah as Chief Executive Officer

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.09 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.046 loss in 1Q 2022)

Scilex Holding Company's (NASDAQ:SCLX) 56% Dip In Price Shows Sentiment Is Matching Earnings

Scilex Holding Company Announces Complete Enrollment of A Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (Lidocaine Topical System) 5.4%, Triple Strength Formulation of Ztlido, for the Treatment of Acute Low Back Pain

Full year 2022 earnings released: US$0.17 loss per share (vs US$0.45 loss in FY 2021)

Scilex Holding Company Acquires Rights to FDA-Approved ELYXYB in the U.S. and Canada for the Acute Treatment of Migraine

Scilex Holding Company, Annual General Meeting, Apr 06, 2023

High number of new and inexperienced directors

Third quarter 2022 earnings released

Scilex Holding Company announced that it expects to receive $500 million in funding from Yorkville Advisors Global LP

Less than half of directors are independent

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş